5 / 22
conferenceseries LLC Ltd
Notes:
Page 36
Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X
Volume 7
September 18-19, 2018 | Amsterdam, Netherlands
6
th
European Biopharma Congress
Euro Biopharma 2018
Nanobiotechnology-based drugs for treatment of neurological disorders
Alain L Fymat
International Institute of Medicine and Science, USA
T
here are approximately 400 known neural disorders, some being due to a disruption or failure of the blood brain barrier (BBB) such as,
e.g.,
meningitis, epilepsy, multiple sclerosis, prion and prion-like diseases (Parkinson's, Alzheimer's), HIV encephalitis, and systemic
inflammation (sterile or infectious). As a consequence of the growing aging population, many such neurodegenerative diseases, cancer,
and infections of the brain will become more prevalent. Unfortunately, the developmental process for new drugs has not kept pace with
progress in molecular neuroscience because most of the new drugs discovered are unable to cross the BBB. This clinical failure may be
largely attributed to a lack of appropriate drug delivery systems. Of interest here are those disorders requiring treatment by delivery of
nanobiotechnology (NBT)-based drugs through the BBB-one of the most promising applications in clinical neuroscience. Nanoparticles,
utilized as drug delivery agents, could potentially carry out multiple tasks in a predefined sequence. They can be effective careers in
delivery of conventional drugs, recombinant proteins, vaccines,
etc.
The following nanotechnologies are available: liposomes, peptides,
radiolabeled polyethylene glycol coated hexadecylcyanoacrylate nanospheres, polyalkylcyanoacrylate or poly-lactic-co-glycolic acid
(PLGA) nanoparticles with polysorbate 80 or poloxamer, and magneto-electric nanoparticles (MENs). Localized and controlled delivery
of drugs at their desired sites of action is preferred because it reduces toxicity and increases treatment efficiency. I will discuss the various
strategies that have been explored to increase drug delivery into the brain and their attending difficulties, with particular emphasis on NBT-
based drug delivery systems. However, although the use of nanotechnology is expected to reduce the need for invasive procedures for
delivery of therapeutics, some devices such as implanted catheters and reservoirs will still be needed. Further, there is some concern about
the safety of nanoparticle entry in the brain and these needs to be resolved before human use.
alain.fymat@fiimas.orgClin Pharmacol Biopharm 2018, Volume:7
DOI: 10.4172/2167-065X-C1-029